Trans

TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment

LOD, Israel--(BUSINESS WIRE)--Jul 9, 2007 - TransPharma MedicalLtd., a specialty pharmaceutical company focused on the developmentand commercialization of drug products utilizing a proprietaryactive transdermal drug delivery technology, announced todaypromising results of its phase I clinical trials demonstrating thesafety and pharmacokinetic profile of its ViaDerm-hPTH (1-34)product for th...

Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival

- New Data from Phase III Intergroupe Francophone du Myelome (IFM)Trial Presented During IMW - CAMBRIDGE, Mass., July 02, 2007 /PRNewswire-FirstCall/ --Millennium Pharmaceuticals, Inc. today reported that new data werepresented on the comparative Phase III clinical trial evaluating aVELCADE based therapy in newly diagnosed multiple myeloma (MM)patients. As induction therapy prior to stem...

A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients

Final Results from Exploratory Phase IIa Clinical Trial in Type 2Diabetes Patients Announced TORONTO, June 28, 2007 /PRNewswire-FirstCall/ - TransitionTherapeutics Inc. ("Transition") , today announces the results fromits exploratory Phase IIa clinical trial indicating that 4-weeks ofdaily treatments with gastrin-based therapy, E1-I.N.T.(TM), showedsustained reductions in blood glucose co...

AMIA Announces 2008 Summit on Translational Bioinformatics

Program to address a broad range of topics coveringresearch-related issues and best practices in bioinformatics andcomputational biology BETHESDA, Md., June 21, 2007 /PRNewswire-USNewswire/ -- TheAmerican Medical Informatics Association (AMIA) Board of Directors,in support of its strategic plan, has approved the development ofan annual meeting that will explore topics related to translati...

NuPathe Reports Positive Phase One Results for NP101 Transdermal Therapy for Acute Migraine

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Jun 8, 2007 - NuPathe Inc., aprivately held specialty pharmaceutical company, today announcedpositive results from an initial Phase I study of NP101SmartRelief, a novel treatment for acute migraine being developedby NuPathe. NP101 combines NuPathe's SmartRelief(TM) proprietaryiontophoretic transdermal technology with sumatriptan, the mostwidely prescri...

Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain

STANFORD, Calif.--(BUSINESS WIRE)--Jun 4, 2007 - Researchers at theStanford University School of Medicine have illuminated the pathtaken by human neural stem cells that were transplanted into thebrains of rats and mice, and found that the cells successfullynavigate toward areas damaged by stroke. The research group placed miniscule particles of iron insidestem cells to act as cellular bea...

LifeCycle Pharma Announces Positive Phase I Clinical Results for its Transplantation Product Candidate, LCP-Tacro

Heads into US Phase II Clinical Trials for Organ Transplantation HORSHOLM, Denmark, May 31, 2007 /PRNewswire-FirstCall/ --LifeCycle Pharma announces positive Phase I clinical results forits transplantation product candidate, LCP-Tacro - Heads into USPhase II clinical trials for organ transplantation. Today LifeCycle Pharma A/S (OMX:LCP) announces positive resultsfrom its Phase I cli...

Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plcannounced today that DAYTRANA(TM) (methylphenidate transdermalsystem), its Attention Deficit Hyperactivity Disorder (ADHD) patch,had significant efficacy in reducing the symptoms of ADHD in bothmale and female children aged 6 to 12 years, according to clinicaltrial results reported at the American Psychiatric Association(APA) ann...

12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plcannounced that DAYTRANA(TM) (methylphenidate transdermal system),the first and only non-oral medication approved for treatment ofAttention Deficit Hyperactivity Disorder (ADHD) in children aged 6to 12 years, provided significant improvement in symptom controland tolerability, according to results of a 12-month open-labelstudy pre...

Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent

Moffitt Research Presented at 9th International Symposium onMyelodysplastic Syndromes TAMPA, Fla., May 17, 2007 /PRNewswire/ -- New updated resultsfrom a pivotal Phase II trial evaluating Revlimid in patients withan incurable blood cancer known as myelodysplastic syndromes (MDS)were presented today by Dr. Alan List, from the H. Lee MoffittCancer Center & Research Institute, at the 9th...

AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin Cells Have the Ability to Recognize, Transport and Utilize L-ergothioneine (EGT) As A Protector Against Oxidative Damage

Clinical Poster Presented at Society for Investigative Dermatology FREEPORT, N.Y., May 16, 2007 /PRNewswire/ -- AGI Dermaticsrecently announced new comparative clinical data that indicatesthat OCTN-1 skin cells have the ability to recognize, transport andutilize L-ergothioneine (EGT) as a protector against oxidativedamage, and importantly, that (EGT) acts as a more powerful andefficient a...

KineMed Presents Data Measuring Changes in Reverse Cholesterol Transport for the First Time

Research Breakthrough Will Aid in Developing Therapies to Preventand Reverse Atherosclerotic Heart Disease EMERYVILLE, Calif., May 10, 2007 /PRNewswire/ -- KineMed, Inc.,a pathway-based drug discovery and development company, announcedtoday the first method for measuring the efflux of cholesterol fromtissues in animals through the pathway known as reverse cholesteroltransport (RCT). RCT i...

Bema Fentanyl Demonstrates Substantial Transmucosal Delivery In Absolute Bioavailability Study

MORRISVILLE, N.C.--(BUSINESS WIRE)--May 7, 2007 - BioDeliverySciences International, Inc. (Nasdaq:BDSI) announced the results ofa 12 subject, crossover study comparing the absorption of fentanylfrom both single and multiple BEMA(TM) Fentanyl discs, as well asoral and intravenous doses of fentanyl. The data demonstrates thatthe absolute bioavailability (i.e. the total amount absorbed fromthe...

Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial

EDMONTON, May 07, 2007 /PRNewswire-FirstCall/ - Isotechnika Inc.today announced the audited three month results, reviewed by theData Monitoring Committee, of the first third of the patientstreated in its Phase 2b de novo kidney transplant trial for theCompany's lead immunosuppressive drug, ISA247. This interim analysis is based upon the assessment of the first116 patients enrolled....

Argos Therapeutics Presents Immunosuppression Data for Soluble CD83 at the American Society of Transplantation Congress 2007

DURHAM, N.C.--(BUSINESS WIRE)--May 4, 2007 - Argos Therapeuticstoday announced the presentation of data on the immunosuppressiveproperties of soluble CD83 at the 7th Joint American Transplantmeeting to be held in San Francisco, May 5-9. The presentationswill be made in collaboration with scientists at the University ofWestern Ontario. "These data suggest that soluble CD83 is able to exten...

Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter

MELBOURNE, Australia, May 03, 2007 /PRNewswire-FirstCall/ --Phosphagenics Limited (AIM: PSG) announced today that the Companyintends to initiate a Phase 1b clinical trial to demonstrate theefficacy and safety of the improved formulation of its transdermalinsulin product, TPM-02/Insulin, containing long-acting insulin.The trial is expected to commence in the second quarter of2007....

Schepens Scientists Identify Key to Integrating Transplanted Nerve Cells Into Injured Tissue

Discovery promises to make retina, spinal cord and other centralnervous system transplants possible BOSTON, April 26, 2007 /PRNewswire/ -- Scientists at theSchepens Eye Research Institute, an affiliate of Harvard MedicalSchool, have identified a key mechanism for successfullytransplanting tissue into the adult central nervous system. Thestudy found that a molecule known as MMP-2 (which is...

Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice with Transplant of Purified Donor Blood Stem Cells

SAN CARLOS, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - CellerantTherapeutics today announced the publication of data suggestingthat established autoimmune disease can be reversed or stabilizedby the transplantation of purified allogeneic (donated)hematopoietic (blood forming) stem cells (HSC) in a mouse study ofSystemic Lupus Erythematosus (SLE). Subjects that underwent thisprocedure exhibited...

New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting

ADDISON, Texas, April 19, 2007 /PRNewswire/ -- New clinicaltrial results for heart transplant patients will be released at theupcoming International Society for Heart and Lung Transplantation(ISHLT) 27th Annual Meeting and Scientific Sessions at the HiltonSan Francisco, April 25-28, 2007. Results show promise for efficacyand safety of immunosuppression therapy and lower incidences ofacut...

Novel Human Tissue Transgenic Cancer Model May Offer Significant Advance Toward Accurately Modeling Human Cancer

LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 -AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused onthe discovery and development of novel, targeted cancer medicines,presented today findings from its novel human-in-mouse (HIM) tissuetransgenic cancer model system, in which AVEO successfully createdinvasive human tumors that develop over time in mice from prim...

Isotechnika's independent data monitoring committee conducts review of phase 2b kidney transplant trial

- Company Set to Host Evening Symposium at ATC - EDMONTON, March 27 /CNW/ - Isotechnika Inc. announced today thatan independent data monitoring committee (DMC) has met and reviewedthe interim data from the Phase 2b kidney transplant (PROMISE)trial. The review included 3 month data from approximately 1/3 ofthe anticipated 332 patients to be enrolled. The DMC hasrecommended that...